Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Equivalents: 2021-2025

Historic Cash & Equivalents for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $59.6 million.

  • ARS Pharmaceuticals' Cash & Equivalents rose 50.18% to $59.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.6 million, marking a year-over-year increase of 50.18%. This contributed to the annual value of $50.8 million for FY2024, which is 28.40% down from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Cash & Equivalents is $59.6 million, which was up 15.55% from $51.5 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Cash & Equivalents' 5-year high stood at $374.2 million during Q1 2021, with a 5-year trough of $36.6 million in Q2 2024.
  • Its 3-year average for Cash & Equivalents is $61.1 million, with a median of $56.0 million in 2024.
  • In the last 5 years, ARS Pharmaceuticals' Cash & Equivalents soared by 250.50% in 2022 and then plummeted by 70.21% in 2023.
  • Over the past 5 years, ARS Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $60.1 million in 2021, then skyrocketed by 250.50% to $210.5 million in 2022, then crashed by 66.29% to $71.0 million in 2023, then decreased by 28.40% to $50.8 million in 2024, then soared by 50.18% to $59.6 million in 2025.
  • Its Cash & Equivalents was $59.6 million in Q3 2025, compared to $51.5 million in Q2 2025 and $39.9 million in Q1 2025.